| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1524-4741.2011.01175.X |
| P698 | PubMed publication ID | 22098334 |
| P2093 | author name string | Pierre Fumoleau | |
| Monica Fornier | |||
| P2860 | cites work | How basal are triple-negative breast cancers? | Q40105023 |
| Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro | Q40176252 | ||
| Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers | Q42448782 | ||
| Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes | Q42451354 | ||
| Breast cancer molecular subtypes respond differently to preoperative chemotherapy | Q42482998 | ||
| Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes | Q42500568 | ||
| Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry | Q42510173 | ||
| The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes | Q42511189 | ||
| Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database | Q42515557 | ||
| Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple-negative' breast cancers | Q42517062 | ||
| Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer | Q42653377 | ||
| Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy | Q44423612 | ||
| Clinicopathologic and prognostic characteristics of triple-negative breast cancer | Q45084404 | ||
| Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer. | Q46121546 | ||
| Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer | Q46201981 | ||
| Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers | Q46301105 | ||
| Platinum-based chemotherapy in triple-negative breast cancer. | Q46358330 | ||
| Impact of triple negative phenotype on breast cancer prognosis | Q46461211 | ||
| Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox | Q46509413 | ||
| The prognostic importance of triple negative breast carcinoma | Q46616730 | ||
| Is triple negative a prognostic factor in breast cancer? | Q46679901 | ||
| Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane | Q46696565 | ||
| Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer | Q46771645 | ||
| Risk factors for triple-negative breast cancer in women under the age of 45 years | Q24644075 | ||
| High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs | Q24644255 | ||
| Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers | Q27851474 | ||
| Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy | Q27860519 | ||
| Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications | Q27860709 | ||
| Repeated observation of breast tumor subtypes in independent gene expression data sets | Q28131820 | ||
| Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer | Q29614302 | ||
| Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study | Q33386059 | ||
| Iniparib plus chemotherapy in metastatic triple-negative breast cancer | Q33393514 | ||
| Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases | Q33715354 | ||
| Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer | Q34601123 | ||
| Epidemiology of basal-like breast cancer | Q34639174 | ||
| Triple-negative breast cancer: clinical features and patterns of recurrence | Q34658655 | ||
| Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342 | Q35633680 | ||
| Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes | Q35894040 | ||
| A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer | Q36276485 | ||
| Early onset of breast cancer in a group of British black women | Q36614754 | ||
| Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes | Q37175571 | ||
| Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models | Q37208563 | ||
| Triple-negative breast cancers are increased in black women regardless of age or body mass index | Q37208769 | ||
| Survival among women with triple receptor-negative breast cancer and brain metastases | Q37293398 | ||
| What is triple-negative breast cancer? | Q37325246 | ||
| Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors | Q37352494 | ||
| Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design | Q37418501 | ||
| Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study | Q39605778 | ||
| High prevalence of triple-negative tumors in an urban cancer center | Q39846699 | ||
| Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer | Q39893964 | ||
| P433 | issue | 1 | |
| P921 | main subject | ixabepilone | Q11711607 |
| P304 | page(s) | 41-51 | |
| P577 | publication date | 2011-11-20 | |
| P1433 | published in | The Breast Journal | Q15749274 |
| P1476 | title | The paradox of triple negative breast cancer: novel approaches to treatment | |
| P478 | volume | 18 |
| Q30277052 | "An addendum to breast cancer": the triple negative experience |
| Q37438076 | 5-FU and ixabepilone modify the microRNA expression profiles in MDA-MB-453 triple-negative breast cancer cells |
| Q98237769 | ATIP3 deficiency facilitates intracellular accumulation of paclitaxel to reduce cancer cell migration and lymph node metastasis in breast cancer patients |
| Q35651216 | Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients |
| Q35803370 | Clinical efficacy of administering oxaliplatin combined with S-1 in the treatment of advanced triple-negative breast cancer |
| Q39634771 | First-in-Human Phase 1 Studies in Oncology: The New Challenge for Investigative Sites |
| Q35225064 | Folate receptor-α (FOLR1) expression and function in triple negative tumors |
| Q92572651 | Glutathione peroxidase-1 regulates adhesion and metastasis of triple-negative breast cancer cells via FAK signaling |
| Q37438041 | Impact of radiation therapy on survival in patients with triple-negative breast cancer |
| Q26779880 | Liver Metastasis of a Triple-Negative Breast Cancer and Complete Remission for 5 Years After Treatment With Combined Bevacizumab/Paclitaxel/Carboplatin: Case Report and Review of the Literature |
| Q35950656 | MiR-34b is associated with clinical outcome in triple-negative breast cancer patients |
| Q60312883 | Potential Management of Circulating Tumor DNA as a Biomarker in Triple-Negative Breast Cancer |
| Q37385219 | RGD-conjugated mesoporous silica-encapsulated gold nanorods enhance the sensitization of triple-negative breast cancer to megavoltage radiation therapy |
| Q37697013 | Relationship between tumor heterogeneity measured on FDG-PET/CT and pathological prognostic factors in invasive breast cancer. |
| Q41612892 | T-cadherin is associated with prognosis in triple-negative breast cancer |
| Q37477489 | Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis |
| Q47243874 | Targeting LC3 and Beclin-1 autophagy genes suppresses proliferation, survival, migration and invasion by inhibition of Cyclin-D1 and uPAR/Integrin β1/ Src signaling in triple negative breast cancer cells |
| Q92190740 | Targeting of the Eukaryotic Translation Initiation Factor 4A Against Breast Cancer Stemness |
| Q37395716 | Telomerase reverse transcriptase promotes cancer cell proliferation by augmenting tRNA expression |
| Q53823804 | The dysregulation of tRNAs and tRNA derivatives in cancer. |
| Q26775232 | The fate of chemoresistance in triple negative breast cancer (TNBC) |
| Q37304764 | The potential role of nanotechnology in therapeutic approaches for triple negative breast cancer |
| Q37645090 | Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway. |
| Q34646376 | Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents |
Search more.